198 related articles for article (PubMed ID: 37012881)
1. Advances in the application of immune checkpoint inhibitors in gynecological tumors.
Zou Y; Xu Y; Chen X; Zheng L
Int Immunopharmacol; 2023 Apr; 117():109774. PubMed ID: 37012881
[TBL] [Abstract][Full Text] [Related]
2. The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers.
Chelariu-Raicu A; Zibetti Dal Molin G; Coleman RL
Int J Gynecol Cancer; 2020 Oct; 30(10):1608-1618. PubMed ID: 32928926
[TBL] [Abstract][Full Text] [Related]
3. Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer.
Shim SH; Lee JY; Lee YY; Park JY; Lee YJ; Kim SI; Han GH; Yang EJ; Noh JJ; Yim GW; Son JH; Kim NK; Kim TH; Kong TW; Choi YJ; Cho A; Lim H; Jang EB; Cho HW; Suh DH
J Gynecol Oncol; 2024 Mar; 35(2):e66. PubMed ID: 38330382
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic vaccines and immune checkpoints inhibition options for gynecological cancers.
Di Tucci C; Schiavi MC; Faiano P; D'Oria O; Prata G; Sciuga V; Giannini A; Palaia I; Muzii L; Benedetti Panici P
Crit Rev Oncol Hematol; 2018 Aug; 128():30-42. PubMed ID: 29958629
[TBL] [Abstract][Full Text] [Related]
5. Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer.
Lorusso D; Ceni V; Muratore M; Salutari V; Nero C; Pietragalla A; Ciccarone F; Carbone V; Daniele G; Scambia G
Expert Opin Emerg Drugs; 2020 Dec; 25(4):445-453. PubMed ID: 33040627
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?
Taha T; Reiss A; Amit A; Perets R
BioDrugs; 2020 Dec; 34(6):749-762. PubMed ID: 33141420
[TBL] [Abstract][Full Text] [Related]
7. Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?
Lee SM; Lee S; Cho HW; Min KJ; Hong JH; Song JY; Lee JK; Lee NW
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674491
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
Peng H; He X; Wang Q
Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
[TBL] [Abstract][Full Text] [Related]
9. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
10. Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers.
Noh JJ; Kim MK; Choi MC; Lee JW; Park H; Jung SG; Joo WD; Song SH; Lee C
Cancer Res Treat; 2022 Oct; 54(4):1200-1208. PubMed ID: 34902958
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant.
Yang C; Xia BR; Zhang ZC; Zhang YJ; Lou G; Jin WL
Front Immunol; 2020; 11():577869. PubMed ID: 33123161
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions.
Kagabu M; Nagasawa T; Sato C; Fukagawa Y; Kawamura H; Tomabechi H; Takemoto S; Shoji T; Baba T
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230938
[TBL] [Abstract][Full Text] [Related]
13. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.
Wang Q; Peng H; Qi X; Wu M; Zhao X
Signal Transduct Target Ther; 2020 Jul; 5(1):137. PubMed ID: 32728057
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1.
Lefler DS; Snook AE; Bashir B
Immunotherapy; 2022 Aug; 14(11):885-902. PubMed ID: 35694998
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy.
Schepisi G; Casadei C; Toma I; Poti G; Iaia ML; Farolfi A; Conteduca V; Lolli C; Ravaglia G; Brighi N; Altavilla A; Martinelli G; De Giorgi U
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671294
[TBL] [Abstract][Full Text] [Related]
17. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
Front Immunol; 2020; 11():574271. PubMed ID: 33162990
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer.
Muaibati M; Abuduyilimu A; Zhang T; Dai Y; Li R; Huang F; Li K; Tong Q; Huang X; Zhuang L
Expert Rev Mol Med; 2023 Jan; 25():e6. PubMed ID: 36691778
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
[TBL] [Abstract][Full Text] [Related]
20. [Place of PARP inhibitors in the treatment of endometrial and cervical cancers].
Le Gac M; Koual M; Delanoy N; Perkins G; Nguyen-Xuan HT; Blons H; Le Frère-Belda MA; Laurent-Puig P; Bentivegna E; Durdux C; Azaïs H; Bats AS
Bull Cancer; 2022 Jan; 109(1):65-75. PubMed ID: 34801228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
